Use of methotrexate in young patients with respect to the reproductive system

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Gromnica Ihle, E ^a   Kruger K ^b  

^a Rheumatology   (Germany)

^b Center for Clinical Rheumatology Research   (Germany)

Author keywords

Methotrexate; Reproductive system; Rheumatology

Indexed keywords

AMINOPTERIN; ANTIRHEUMATIC AGENT; CYTOSTATIC AGENT; FOLIC ACID ANTAGONIST; METHOTREXATE;

ABORTION; ARTICLE; BREAST FEEDING; BREAST MILK; CAVERNOUS HEMANGIOMA; CHORIOCARCINOMA; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COHORT ANALYSIS; CONCEPTION; CONGENITAL MALFORMATION; DRUG ANTAGONISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG WITHDRAWAL; EAR MALFORMATION; ECTOPIC PREGNANCY; ENVIRONMENTAL EXPOSURE; FEMALE GENITAL SYSTEM; FETAL AMINOPTERIN LIKE SYNDROME; FETUS DISEASE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; FOLIC ACID DEFICIENCY; FOOD AND DRUG ADMINISTRATION; HAIRLINE MALFORMATION; HUMAN; HYDROCEPHALUS; HYPERTELORISM; HYPOPLASIA; JUVENILE RHEUMATOID ARTHRITIS; LACTATION; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MICROCEPHALY; MICROGNATHIA; OLIGOSPERMIA; PATIENT COUNSELING; PATIENT EDUCATION; PLACENTA; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PSORIASIS; RECURRENT ABORTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONTANEOUS ABORTION; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR; AWARENESS; DRUG CONTRAINDICATION; FOLLOW UP; GENITAL SYSTEM; PATERNAL EXPOSURE; PREGNANCY; SUPPLEMENTATION; TRISOMY 16;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; AGE FACTORS; ANTIRHEUMATIC AGENTS; BREAST FEEDING; FEMALE; FERTILITY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; METHOTREXATE; MILK, HUMAN; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78650540402     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. SCIALLI AR, BUELKE-SAM JL, CHAMBERS CD et al.: Communicating risks during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 2004;70:7-12.
2. BARNHART KT: Clinical practice. Ectopic pregnancy. N Engl J Med 2009;361:379-87.
3. STUTZMAN L, SOKAL JE: Use of anticancer drugs during pregnancy. Clin Obstet Gynecol 1968;11:416-27.
4. SKALKO RG, GOLD MP: Teratogenicity of methotrexate in mice. Teratology 1974;9:159-63.
5. LLOYD M E, CARR M, MCELHATTON P, HALL G M, HUGHES RA: The effects of methotrexate on pregnancy, fertility and lactation. Q J Med 1999;92:551-63.
6. BANNWARTH B, PÉHOURCQ F, SCHAEVERBEKE T, DEHAIS J: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
7. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN PT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
8. FELDKAMP M, CAREY JC: Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993;47:533-9.
9. BAWLE EV, CONARD JV, WEISS L: Adult and two children with fetal methotrexate syndrome. Teratology 1998;57:51-5.
10. ØSTENSEN M: Management of early aggressive rheumatoid arthritis during pregnancy and lactation. Expert Opin Pharmacother 2009;10:1469-79.
11. SEIDAHMED MZ, SHAHEED MM, ABDULBASIT OB et al.: A case of methotrexate embryopathy with holoprosencephaly, expanding the phenotype. Birth Defects Res A Clin Mol Teratol 2006;76:138-42.
12. DINIZ EM, CORRADINI HB, RAMOS JL, BROCK R: Effect, on the fetus, of methotrexate (amethopterin) administered to the mother. Presentation of a case. Rev Hosp Clin Fac Med Sao Paulo 1978;33:286-90.
13. BUCKLEY LM, BULLABOY CA, LEICHTMAN L, MARQUEZ M: Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997;40:971-3.
14. MARTÍNEZ LOPEZ JA, LOZA E, CARMONA L: Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27:678-84.
15. ØSTENSEN M, VON ESEBECK M, VILLIGER PM: Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 2007;34:1266-9.
16. KOZLOWSKI RD, STEINBRUNNER JV, MACKENZIE AH, CLOUGH JD, WILKE WS, SEGAL AM: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-92.
17. DONNENFELD AE, PASTUSZAK A, NOAH JS, SCHICK B, ROSE NC, KOREN G: Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79-81.
18. ØSTENSEN M, HARTMANN H, SALVESEN K: Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000;27:1872-5.
19. CHAKRAVARTY EF, SANCHEZ-YAMAMOTO D, BUSH TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-6.
20. LEWDEN B, VIAL T, ELEFANT E, NELVA A, CARLIER P, DESCOTES J: French Network of Regional Pharmacovigilance Centers. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 2004;31:2360-5.
21. REGAN L, RAI R: Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:839-54.
22. SCHAEFER C, SPIELMANN H, VETTER K (Eds.): Arzneiverordnung in Schwangerschaft und Stillzeit. 7th ed. Elsevier GmbH: Urban & Fischer Verlag 2006:3.
23. EL-BEHEIRY A, EL-MANSY E, KAMEL N, SALAMA N: Methotrexate and fertility in men. Arch Androl 1979;3:177-9.
24. MORRIS LF, HARROD MJ, MENTER MA, SILVERMAN AK: Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993;29:913-6.
25. SUSSMAN A, LEONARD JM: Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980;116:215-7.
26. FRENCH AE, KOREN G; MOTHERISK TEAM: Effect of methotrexate on male fertility. Can Fam Physician 2003;49:577-8.
27. LEE CY, JIN C, MATA AM, TANAKA T, EINARSON A, KOREN G: A pilot study of paternal drug exposure: the Motherisk experience. Reprod Toxicol 2010;29:353-60.
28. HOELTZENBEIN M, WEBER-SCHÖNDORFER C, VON STACKELBERG L, SCHAEFER C: Paternal exposure to drugs - Is there an increased risk for congenital abnormalities? Experience of the Berlin Institute of Clinical Teratology and Drug Risk Assessment during Pregnancy (Abstract). Med Genetik 2008;20:166.
29. JOHNS DG, RUTHERFORD LD, LEIGHTON PC, VOGEL CL: Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972;112:978-80.
30. AVILÉS A, NERI N: Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001;2:173-7.
31. NEEMAN N, ARONSON MD, SCHULZE JE, SHMERLING RH: Improving pregnancy counseling for women with rheumatoid arthritis taking methotrexate. Am J Med 2009;122:998-1000.
32. VIKTIL KK, ENGELAND A, FURU K: Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study. Pharmacoepidemiol Drug Saf 2009;18:737-42.
33. ØSTENSEN M, KHAMASHTA M, LOCKSHIN M et al.: Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209. Epub 2006 May 11.
34. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
35. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
36. RODDY E, ZHANG W, DOHERTY M et al.: Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 2006;12:347-52.
37. ELLIOTT AB, CHAKRAVARTY EF: Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health (Lond Engl) 2010;6:431-40.